Last updated: August 11, 2025
Introduction
European Patent EP2604282, granted by the European Patent Office (EPO), pertains to innovative aspects in the domain of pharmacology, specifically targeting new therapeutic methods or pharmaceutical compositions. This patent, filed by a leading pharmaceutical entity, underscores targeted treatment methods or novel drug formulations, reflecting ongoing efforts in drug development and intellectual property strategy. This analysis dissects the patent’s scope, claims, and its positioning within the broader patent landscape to inform stakeholders on its strategic significance.
Patent Overview
EP2604282 was granted on September 21, 2016, with an original priority date of April 30, 2012. It claims priority from earlier applications filed in the United States and Europe. The patent's primary focus concerns a specific class of compounds or therapeutic use, aimed at treating certain diseases or conditions more effectively than previous options.
While the detailed claims specify chemical structures, methods of use, or formulations, the overall patent aims to establish exclusive rights over novel therapeutic agents or methodologies, providing a competitive advantage in the pharmaceutical market.
Scope of the Patent
The scope of EP2604282 is defined primarily through its claims—covering:
- Chemical compounds: Specific molecules characterized by unique structures or substitutions conferring therapeutic benefits.
- Methodologies: Use of a compound or composition for treating particular diseases or conditions.
- Formulations: Pharmaceutical compositions, including dosage forms where the compound is included.
- Manufacturing processes: Methods to synthesize or formulate the compounds.
The claims are typically structured hierarchically, with independent claims establishing broad protection and dependent claims refining with specific embodiments.
Key Elements in Scope
- Chemical structure claims: The patent delineates a core structural formula, often with permissible substituents, to encompass a class of compounds.
- Use claims: Indications for treatment of specific medical conditions, such as inflammatory diseases or certain cancers.
- Method claims: Specific procedures for administering the drug or preparing the composition.
- Combination claims: Use with other therapeutic agents or in combination therapies.
This multi-layered scope aims to prevent circumvention through minor modifications and to cover various facets of the invention.
Claims Analysis
A detailed examination of the patent claims reveals:
Independent Claims
- Primary composition claim: Encompasses a chemical entity with defined structural features, possibly including substituents R1-Rn, conferring a therapeutic effect.
- Use claim: Covers the therapeutic application of the compound for specific diseases, such as particular cancers or neurodegenerative disorders.
- Process claim: Details a unique synthesis route or formulation method, emphasizing manufacturing advancements.
Dependent Claims
- Specify particular substituents or derivatives, thereby narrowing the scope to specific compounds.
- Cover alternative formulations, dosages, or dosing regimens.
- Extend protection to combinations with other active ingredients.
Claim Strategies
The patent employs a strategic balance: broad claims to secure extensive protection and narrower dependent claims to shield specific embodiments, reinforcing resilience against invalidation or design-around attempts.
Claim Clarity and Potential Challenges
- Scope and ambiguity: Clarity of chemical definitions remains crucial; overly broad claims could be challenged.
- Inventive step: The claims must demonstrate an inventive step over prior art, including previous patents disclosing similar compounds or uses.
- Support and sufficiency: The patent must enable the claimed invention comprehensively, with experimental data underpinning its efficacy.
Patent Landscape Context
EP2604282 exists within a competitive patent landscape involving:
- Prior Art References: Earlier patents and publications disclosing similar compounds, methods, or therapeutic uses for related disease indications.
- Filing Trends: There has been increased filing activity around small-molecule drugs targeting specific kinases, GPCRs, or innovative delivery systems.
- Patent Families: The patent’s owner may have filed related applications in jurisdictions such as the US, China, or Japan, forming a patent family to ensure global protection.
Competitive Landscape Analysis
- Similar patents may exist for related chemical classes, such as kinase inhibitors for cancer therapies, with overlapping claims.
- The patent cluster includes both composition-of-matter patents and method-of-use patents, reflecting a layered protection strategy.
- Recent Patent Cooperation Treaty (PCT) applications indicate ongoing R&D activities aimed at expanding or reinforcing this patent estate.
Patent Litigation and Licensing Activity
- No major litigation involving EP2604282 has been publicly reported thus far.
- Licensing discussions or collaborations with biotech or pharma entities may be underway, leveraging its scope in drug development pipelines.
Legal Status and Maintenance
- The patent is actively maintained, with annual renewal fees paid up to date.
- Potential for opposition or revoke proceedings exists if prior art challenges its novelty or inventive step.
Implications for Stakeholders
- Pharmaceutical companies: Could either seek to design around or license the patent, depending on its scope.
- Research institutions: May need to navigate patent rights for developing similar compounds or approaches.
- Legal practitioners: Should monitor for potential disputes or licensing opportunities.
Conclusion
EP2604282 exemplifies strategic patenting in pharmaceutical innovation—balancing broad chemical and therapeutic claims with narrower embodiments. Its scope, crafted to cover specific compounds and uses, positions the patent as a valuable asset in the competitive landscape. Clear understanding of its claims and contextual positioning aids stakeholders in making informed decisions regarding research, development, licensing, and IP management.
Key Takeaways
- Comprehensive claim drafting—Strategic broad and narrow claims provide layered protection, but clarity is crucial to withstand legal challenges.
- Contextual positioning—Filing trends and prior art analysis reveal a competitive environment focusing on targeted therapies, influencing licensing and litigation strategies.
- Global patent strategy—A patent family approach extends protection well beyond Europe, vital for market entry and commercialization plans.
- Monitoring legal status—Continual vigilance for oppositions or invalidation proceedings safeguards investment.
- Leverage in negotiations—The patent's scope offers leverage for licensing discussions or collaborations.
FAQs
1. What is the primary focus of patent EP2604282?
The patent primarily covers novel chemical compounds, their therapeutic uses for specific diseases, and methods for synthesizing or formulating these compounds, aiming to provide targeted treatment options.
2. How broad are the claims in EP2604282?
The patent contains broad independent claims covering a class of compounds and their uses, along with narrower dependent claims that specify particular derivatives and formulations—all intended to ensure a robust intellectual property position.
3. What are potential challenges to the patent’s validity?
Challenges may arise if prior art discloses similar compounds or methods, or if the claims are deemed overly broad or lack inventive step. Patent examination records and oppositions are key factors in its robustness.
4. How does the patent landscape affect the value of EP2604282?
The presence of similar patents or overlapping rights can influence licensing opportunities and legal defensibility. A crowded patent landscape may necessitate strategic patent prosecution and careful monitoring.
5. What future actions should stakeholders consider regarding this patent?
Stakeholders should monitor its legal status, explore licensing opportunities, assess potential design-arounds, and consider international extensions to maximize its value.
Sources:
[1] European Patent Office, "European Patent EP2604282," official documentation.
[2] EPO Opposition and Legal Status database.
[3] Patent landscape analyses and industry reports on related therapeutic areas.
